AC Immune to Present at Two Investor
Conferences and Provide Scientific Updates at CTAD
Conference
Lausanne, Switzerland, - October 24, 2017 -
AC Immune SA (NASDAQ: ACIU), a Swiss-based,
clinical stage biopharmaceutical company with a broad pipeline
focused on neurodegenerative diseases, today announced that it will
present at two investor conferences in the fourth quarter 2017, the
Credit Suisse Healthcare Conference in Scottsdale, Arizona, US, and
the Jefferies London Healthcare Conference in London, UK.
Furthermore, AC Immune will provide five updates
on the advancement of its partnered product candidates at the
Clinical Trials in Alzheimer's Disease (CTAD) conference in Boston
on 1-4 November 2017. The updates will cover the anti-Abeta
antibody crenezumab and the anti-Tau antibody RO7105705, both
partnered with Genentech, and the Tau-PET imaging agent, partnered
with Piramal Imaging.
Scientific updates at the CTAD conference -
November 1-4, 2017Location: Boston Park Plaza, Boston, MA,
US
Anti-Tau antibody
- Targeting Tau with RO7105705: Phase 1 results and design of a
Phase 2 study in prodromal-to-mild Alzheimer's
disease
Date : November 2, 2017 | 3:00-3:15pm ET
(9:00-9:15pm CET)Presenter: Oral presentation by Geoffrey A.
Kerchner, MD, PhD - Genentech
Crenezumab
- Characterization of the selective in vivo and in vitro
properties of crenezumab: insights into crenezumab's unique
mechanism of action
Date: November 2, 2017; 2:15-2:30pm ET
(8:15-8 :30pm CET)Presenter: Oral presentation by William J.
Meilandt, PhD - Genentech
- Clinical trial design of CREAD studies: randomized,
double-blind, placebo-controlled, parallel-group Phase 3 studies to
evaluate the efficacy and safety of crenezumab in patients with
prodromal to mild Alzheimer's disease
Date: November 1 and 2, 2017 - Clinical trials
methodology (Theme 1, LBP6)Presenter: Poster presentation by Helen
Lin, MD - Genentech
- Crenezumab pharmacokinetic-pharmacodynamic analysis to describe
the increase in total plasma amyloid beta following treatment in
patients with mild to moderate Alzheimer's disease
Date: November 3 and 4, 2017 - Biomarkers
including plasma (Theme 4, P74)Presenter: Poster presentation by
Kenta Yoshida, PhD - Genentech
Tau-PET imaging agent
- Clinical evaluation of 18F-PI-2620, a next generation Tau-PET
agent in subjects with Alzheimer's disease and progressive
supranuclear palsy
Date : November 2, 2017 | 9:00-9:15am ET
(3:00-3:15pm CET)Presenter: Oral presentation by Andrew Stephens,
MD, PhD - Piramal Imaging
Investor PresentationsCredit Suisse
Healthcare Conference, Scottsdale, AZ - November 6-8,
2017Date: November 7, 2017 | 10:55am MT (7:55pm
CET)Venue: The Phoenician Resort - Track 4 Ballroom GPresenter:
Prof. Andrea Pfeifer, CEO, AC ImmuneA webcast of the presentation
will be available on the Investor Page of AC Immune's website and
will be active for 90 days following the event.
Jefferies London Healthcare Conference,
London, UK - November 15-16, 2017Date: November 16, 2017 |
8:40am BT (7:40am CET)Venue: Waldorf Hilton, London - Room 6
AldwychPresenter: Prof. Andrea Pfeifer, CEO, AC ImmuneA webcast of
the presentation will be available on the Investor Page of AC
Immune's website and will be active for 90 days following the
event.
+++ Save the date - AC Immune KOL
event on December 1, 2017 in New York, NY +++
About AC Immune AC Immune is a clinical stage Swiss-based
biopharmaceutical company focused on neurodegenerative diseases
with four product candidates in clinical trials. The Company
designs, discovers and develops therapeutic and diagnostic products
intended to prevent and modify diseases caused by misfolding
proteins. AC Immune's two proprietary technology platforms create
antibodies, small molecules and vaccines designed to address a
broad spectrum of neurodegenerative indications, such as
Alzheimer's disease. The Company's pipeline features nine
therapeutic and three diagnostic product candidates. The most
advanced of these is crenezumab, an anti-Abeta antibody in phase 3
clinical studies that is being conducted by the collaboration
partner Genentech, a member of the Roche Group. Other
collaborations include Biogen, Janssen Pharmaceuticals, Nestlé
Institute of Health Sciences, Piramal Imaging and Essex
Bio-Technology.
Forward looking statements
This press release contains statements that constitute
"forward-looking statements" within the meaning of Section 27A of
the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934. Forward-looking statements are statements
other than historical fact and may include statements that address
future operating, financial or business performance or AC Immune's
strategies or expectations. In some cases, you can identify these
statements by forward-looking words such as "may," "might," "will,"
"should," "expects," "plans," "anticipates," "believes,"
"estimates," "predicts," "projects," "potential," "outlook" or
"continue," and other comparable terminology. Forward-looking
statements are based on management's current expectations and
beliefs and involve significant risks and uncertainties that could
cause actual results, developments and business decisions to differ
materially from those contemplated by these statements. These risks
and uncertainties include those described under the captions "Item
3. Key Information-Risk Factors" and "Item 5. Operating and
Financial Review and Prospects" in AC Immune's Annual Report on
Form 20-F and other filings with the Securities and Exchange
Commission. Forward-looking statements speak only as of the date
they are made, and AC Immune does not undertake any obligation to
update them in light of new information, future developments or
otherwise, except as may be required under applicable law. All
forward-looking statements are qualified in their entirety by this
cautionary statement.
For further information, please
contact:
In EuropeEva SchierAC Immune Corporate Communications Phone:
+41 21 345 91 34E-mail: eva.schier@acimmune.com |
In the USLisa SherAC Immune Investor Relations Phone: +1 970
987 2654E-mail: lisa.sher@acimmune.com |
Nick Miles /Toomas KullCabinet Privé de Conseils s.a.Phone: +41 22
552 46 46 E-mail: miles@cpc-pr.comkull@cpc-pr.com |
Ted AgneThe Communications Strategy Group Inc.Phone: +1 781 631
3117E-mail: edagne@comstratgroup.com |
Attachments:
http://www.globenewswire.com/NewsRoom/AttachmentNg/1ecaa820-566e-4422-bed8-b95bb1d8e60e
AC Immune (NASDAQ:ACIU)
Historical Stock Chart
From Mar 2024 to Apr 2024
AC Immune (NASDAQ:ACIU)
Historical Stock Chart
From Apr 2023 to Apr 2024